Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2027

Conditions

Multiple Advanced Tumors After PD-1 Therapy Failure

Interventions

DRUG

Ivonescimab (20mg/kg Q3W)

Patients received intravenous everciximab (20mg/kg Q3W) within 1 week before and after radiofrequency ablation.

PROCEDURE

radiofrequency ablation

Patients received radiofrequency treatment for less than three lesions.

All Listed Sponsors

lead

Sheng Zhang

OTHER